Fate Therapeutics, Inc. (FATE) — Stock Score Summary

Fate Therapeutics, Inc. (FATE) has a MoatMap StockRank of 37/100 based on Quality (23/100), Value (38/100), and Momentum (63/100) factor scores. The current signal is HOLD. Fate Therapeutics is an unprofitable, early-stage biotech firm with high cash burn, which violates our Terry Smith quality lens of owning established compounders.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of programmed cellular immunotherapies, specifically induced pluripotent stem cell (iPSC)-derived natural killer (NK) and T-cell product candidates for cancer and autoimmune diseases. Its innovative iPSC platform represents a differentiated approach to cell therapy manufacturing, offering potential for off-the-shelf treatments. The company is a key player in the nascent but rapidly evolving allogeneic cell therapy space.

Key Financial Metrics

Price$1.90
Market Cap$307M
P/E (Forward)-2.39
Price/Book1.43
Return on Equity-55.5%
Return on Invested Capital-52.2%
Debt/Equity42.73
Gross Margin0.0%
Operating Margin-2540.4%
Revenue Growth-20.3%
Free Cash Flow$-50M

Fate Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Fate Therapeutics, Inc.’s (FATE) StockRank?
MoatMap’s StockRank for Fate Therapeutics, Inc. (FATE) is 37/100, with a Hold signal. It is a composite of Quality (23), Value (38), and Momentum (63) factor ranks across MoatMap’s 19,000+ stock universe.
Does Fate Therapeutics, Inc. have an economic moat?
Fate Therapeutics, Inc. (FATE) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Fate Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Fate Therapeutics, Inc. (FATE) is Hold, based on a StockRank of 37/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Fate Therapeutics, Inc. in?
Fate Therapeutics, Inc. (FATE) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksFATE deep dive reportAI ChampionsHow we score stocksSense-check another stock